- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05864261
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
November 20, 2023 updated by: Yi Fang
A Randomized, Blinding, Single-dose, Positive-drug Parallel Control Study to Compare the Pharmacokinetics Following Administration of JT1801 and Darbepoetin Alfa Injection (NESP®) in Chinese Healthy Adult Volunteers
The purpose of this study is to compare the similarity of major pharmacokinetic parameters after a single intravenous administration of JT1801 and NESP® in chinese healthy male volunteers.
And to evaluate the safety, immunogenicity and pharmacodynamic characteristics of JT1801 and NESP® in chinese healthy male volunteers
Study Overview
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 101149
- Peking University People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Chinese healthy adult male subjects.
- Age of 18 to 55 years, inclusive.
- Subject with BMI between 19 kg/m2 and 26 kg/m2 (inclusive); and a total body weight ≥50 kg.
- Subject who agree to practive effective barrier contraception and avoid sperm donation during the entire study period and through at least 3 months after the last dose of study drug.
- Subject who provided written informed consent voluntarily after being fully informed of the study.
- Subject who is able to communicate well with the investigator and participate in the whole study process according to protocol.
Exclusion Criteria:
- During the screening period, vital signs measurement, physical examination, laboratory examination (blood routine, reticulocyte, urine routine, blood biochemistry, coagulation function, anemia, transferrin saturation, IgE detection), B-ultrasound examination, chest X-ray and 12-lead electrocardiogram examination showed abnormal results and were judged by the investigator to be clinically significant.
- History of chronic disease or serious disease in cardiovascular, liver, kidney, biliary tract, respiratory, blood, lymphatic, endocrinological, immunologic, psychiatric, neuromuscular, gastrointestinal system within three years.
- Have a history of specific allergies (e.g. hives) or are allergic (e.g. are known to be allergic to two or more drugs), or have a history of allergy to this ingredient or to EPO drugs.
- Subjects with past or present history of hypertension, stroke, thromboembolism, convulsion, epilepsy or pure red cell aplasia.
- Subject with severe psychological or mental illness.
- Subject with a previous history of tumors.
- The investigator considers that there are other medical conditions that may affect the study results and the safety of the subjects.
- Subject who had surgery within 6 months prior to screening period that the investigators determined would affect drug absorption, distribution, metabolism, or excretion, or who planned to have surgery during the study period.
- Subject who have received other biologics within 6 months.
- Those with a history of drug abuse (including the use of various narcotic drugs and psychotropic substances for non-medical destinations) or positive drug abuse screening (including morphine, methamphetamine, ketamine, dimethylenedioxyamphetamine, tetrahydrocannabinolic acid, etc.) before the test.
- Positive for any of the virological tests, including human immunodeficiency virus, hepatitis C antibody, hepatitis B surface antigen, and treponema pallidum antibody.
- Subjects who have donated blood or lost blood from other reasons within 6 months prior to screening with a total of 400mL or received blood transfusions or used blood products.
- Has a history of alcohol abuse within 1 year prior to screening, whereby drink more than 2 units of alcohol per week on average (1 unit =360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or alcohol breath test results greater than 0.0mg/100 ml.
- In the past year, the average daily consumption of excessive tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup ≈250mL).
- Those who smoked > 5 cigarettes per day within 3 months before screening or could not refrain from smoking during the test.
- Those who have used any drugs (prescription drugs, over-the-counter drugs, vitamins, Chinese herbal medicines, health supplements) within 30 days before enrollment.
- Those who have used systemic glucocorticoids within 3 months before enrollment.
- Those who have participated in other clinical trials within 3 months before enrollment.
- Those who cannot tolerate venipuncture or have a history of needle sickness and blood sickness.
- Those who have special requirements for diet and cannot accept a unified diet.
- Subjects who received the vaccine within 3 months prior to the first dosing, or plan to be vaccinated during the study or within 1 week after the last dosing.
- Those with a low probability of enrollment or poor adherence (such as frailty, physical exhaustion, dehydration or malnutrition, etc.) according to the judgment of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JT1801
|
JT1801, 60ug, IV injection
|
Active Comparator: NESP
|
NESP, 60ug, IV injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t
Time Frame: Pre-dose and after dose 20 days
|
PK parameters comparison between JT1801 and darbepoetin alfa: AUC0-t
|
Pre-dose and after dose 20 days
|
AUC0-∞
Time Frame: Pre-dose and after dose 20 days
|
PK parameters comparison between JT1801 and darbepoetin alfa: AUC0-∞
|
Pre-dose and after dose 20 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TEmax
Time Frame: Pre-dose and after dose 15 days
|
PD parameters comparison between JT1801 and darbepoetin alfa: TEmax of reticulocyte count, hematocrit, hemoglobin concentration, RBC
|
Pre-dose and after dose 15 days
|
Emax
Time Frame: Pre-dose and after dose 15 days
|
PD parameters comparison between JT1801 and darbepoetin alfa: Emax of reticulocyte count, hematocrit, hemoglobin concentration, RBC
|
Pre-dose and after dose 15 days
|
AUEC0-t
Time Frame: Pre-dose and after dose 15 days
|
PD parameters comparison between JT1801 and darbepoetin alfa: AUEC0-t of reticulocyte count, hematocrit, hemoglobin concentration, RBC
|
Pre-dose and after dose 15 days
|
ΔAUEC0-t
Time Frame: Pre-dose and after dose 15 days
|
PD parameters comparison between JT1801 and darbepoetin alfa: ΔAUEC0-t of reticulocyte count, hematocrit, hemoglobin concentration, RBC
|
Pre-dose and after dose 15 days
|
ΔEmax
Time Frame: Pre-dose and after dose 15 days
|
PD parameters comparison between JT1801 and darbepoetin alfa: ΔEmax of reticulocyte count, hematocrit, hemoglobin concentration, RBC
|
Pre-dose and after dose 15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2023
Primary Completion (Actual)
August 28, 2023
Study Completion (Actual)
August 28, 2023
Study Registration Dates
First Submitted
May 9, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 18, 2023
Study Record Updates
Last Update Posted (Actual)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2022-I-JT1801-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Anemia
-
Kumamoto UniversityCompletedHemodialysis | Iron Deficiency Anemia | Chronic Renal Failure | Renal AnemiaJapan
-
UBI Pharma Inc.Completed
-
Peking University First HospitalBeijing Haidian Hospital; Beijing Hospital of Traditional Chinese MedicineCompleted
-
Helwan UniversityCompletedAnemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure AnemiaEgypt
-
Angde Biotech Pharmaceutical Co., Ltd.Recruiting
-
BayerRecruiting
-
Astellas Pharma IncActive, not recruiting
-
PfizerHospira, now a wholly owned subsidiary of PfizerCompletedPregnancy | Lactation | Renal AnemiaFrance, Croatia, Spain, United Kingdom, Germany, Sweden, Bulgaria, Greece, Denmark, Finland, Ireland, Italy
-
Sociedad Española de TrasplanteCompleted
-
Hoffmann-La RocheCompletedChronic Renal AnemiaGreece
Clinical Trials on JT1801 60ug
-
HK inno.N CorporationCompletedHealthy SubjectsKorea, Republic of
-
Wu JiangBeijing Municipal Science & Technology CommissionCompletedVaccination; Complications, Reaction, SerumChina